Skip to main content

Research Repository

Advanced Search

The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation

Hall, Peter S; Mitchell, Elizabeth D.; Smith, Alison F; Cairns, David A; Messenger, Michael; Hutchinson, Michelle; Wright, Judy; Vinall-Collier, Karen; Corps, Claire; Hamilton, Patrick; Meads, David; Lewington, Andrew

Authors

Peter S Hall

Elizabeth D. Mitchell

Alison F Smith

David A Cairns

Michael Messenger

Michelle Hutchinson

Judy Wright

Karen Vinall-Collier

Claire Corps

Patrick Hamilton

David Meads

Andrew Lewington



Abstract

© Queen’s Printer and Controller of HMSO 2018. Background: Acute kidney injury (AKI) is highly prevalent in hospital inpatient populations, leading to significant mortality and morbidity, reduced quality of life and high short- and long-term health-care costs for the NHS. New diagnostic tests may offer an earlier diagnosis or improved care, but evidence of benefit to patients and of value to the NHS is required before national adoption. Objectives: To evaluate the potential for AKI in vitro diagnostic tests to enhance the NHS care of patients admitted to the intensive care unit (ICU) and identify an efficient supporting research strategy. Data sources: We searched ClinicalTrials.gov, The Cochrane Library databases, Embase, Health Management Information Consortium, International Clinical Trials Registry Platform, MEDLINE, metaRegister of Current Controlled Trials, PubMed and Web of Science databases from their inception dates until September 2014 (review 1), November 2015 (review 2) and July 2015 (economic model). Details of databases used for each review and coverage dates are listed in the main report. Review methods: The AKI-Diagnostics project included horizon scanning, systematic reviewing, meta-analysis of sensitivity and specificity, appraisal of analytical validity, care pathway analysis, model-based lifetime economic evaluation from a UK NHS perspective and value of information (VOI) analysis. Results: The horizon-scanning search identified 152 potential tests and biomarkers. Three tests, Nephrocheck® (Astute Medical, Inc., San Diego, CA, USA), NGAL and cystatin C, were subjected to detailed review. The meta-analysis was limited by variable reporting standards, study quality and heterogeneity, but sensitivity was between 0.54 and 0.92 and specificity was between 0.49 and 0.95 depending on the test. A bespoke critical appraisal framework demonstrated that analytical validity was also poorly reported in many instances. In the economic model the incremental cost-effectiveness ratios ranged from £11,476 to £19,324 per quality-adjusted life-year (QALY), with a probability of cost-effectiveness between 48% and 54% when tests were compared with current standard care. Limitations: The major limitation in the evidence on tests was the heterogeneity between studies in the definitions of AKI and the timing of testing. Conclusions: Diagnostic tests for AKI in the ICU offer the potential to improve patient care and add value to the NHS, but cost-effectiveness remains highly uncertain. Further research should focus on the mechanisms by which a new test might change current care processes in the ICU and the subsequent cost and QALY implications. The VOI analysis suggested that further observational research to better define the prevalence of AKI developing in the ICU would be worthwhile. A formal randomised controlled trial of biomarker use linked to a standardised AKI care pathway is necessary to provide definitive evidence on whether or not adoption of tests by the NHS would be of value.

Citation

Hall, P. S., Mitchell, E. D., Smith, A. F., Cairns, D. A., Messenger, M., Hutchinson, M., …Lewington, A. (2018). The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisation. Health Technology Assessment, 22(32), 1-274. https://doi.org/10.3310/hta22320

Journal Article Type Article
Acceptance Date Aug 1, 2017
Publication Date 2018-05
Deposit Date Aug 7, 2019
Publicly Available Date Aug 7, 2019
Journal Health Technology Assessment
Print ISSN 1366-5278
Electronic ISSN 2046-4924
Publisher NIHR Journals Library
Peer Reviewed Peer Reviewed
Volume 22
Issue 32
Pages 1-274
DOI https://doi.org/10.3310/hta22320
Public URL https://hull-repository.worktribe.com/output/1151150
Publisher URL https://www.journalslibrary.nihr.ac.uk/hta/hta22320#/full-report

Files

Report (2.7 Mb)
PDF

Copyright Statement
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Hall et al. under the terms of a commissioning
contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of
private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation,
Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.





You might also like



Downloadable Citations